Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.

Jas BindraIshveen ChopraKyle HayesJohn NiewoehnerMary PanaccioGeorge J Wan

Published in: ClinicoEconomics and outcomes research : CEOR (2023)

The results from this cost-effectiveness analysis indicate that Acthar Gel is a cost-effective, value-based treatment option for advanced symptomatic sarcoidosis compared to the SoC from the US payer and societal perspectives.

Keyphrases

healthcare
palliative care
combination therapy
pain management